AMARIN CORP PLC\UK Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
AMARIN CORP PLC\UK (AMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 5.19 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-02
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 5.19M shares, a 1234.96% increase from fiscal 2024.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 389.00K shares, a 203.91% increase from fiscal 2023.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 128.00K shares, a 39.34% decline from fiscal 2022.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 211.00K shares, a 29.43% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|
| 2025-12-31 | 5.19M shares 10-K · filed 2026-03-02 |
| 2024-12-31 | 389.00K shares 10-K · filed 2025-03-12 |
| 2023-12-31 | 128.00K shares 10-K · filed 2024-02-29 |
| 2022-12-31 | 211.00K shares 10-K · filed 2023-03-01 |
| 2021-12-31 | 299.00K shares 10-K · filed 2022-03-01 |
| 2020-12-31 | 30.00K shares 10-K · filed 2021-02-25 |
| 2019-12-31 | 3.00K shares 10-K · filed 2020-02-25 |
| 2018-12-31 | 12.00K shares 10-K · filed 2019-02-27 |
| 2017-12-31 | 331.00K shares 10-K · filed 2018-02-27 |
| 2016-12-31 | 165.00K shares 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |